References
- Boesz, C., and N. Lloyd. 2008. “Investigating International Misconduct.” Nature 452 (7188): 686–687. doi:https://doi.org/10.1038/452686a.
- Dresser, R. 1993. “Sanctions for Research Misconduct: A Legal Perspective.” Academic Medicine 68 (9 Suppl): S39–S43. doi:https://doi.org/10.1097/00001888-199309000-00032.
- Enserink, M. 2017. “Swedish Plastics Study Fabricated, Panel Finds.” Science 358 (6369): 1367. doi:https://doi.org/10.1126/science.358.6369.1367.
- Godecharle, S., B. Nemery, and K. Dierickx. 2014. “Heterogeneity in European Research Integrity Guidance: Relying on Values or Norms?” Journal of Empirical Research on Human Research Ethics: JERHRE 9 (3): 79–90. doi:https://doi.org/10.1177/1556264614540594.
- Hawkes, N. 2018. “Macchiarini Case: Seven Researchers are Guilty of Scientific Misconduct, Rules Karolinska’s President.” BMJ 361: k2816. doi:https://doi.org/10.1136/bmj.k2816.
- Keranen, L. 2006. “Assessing the Seriousness of Research Misconduct: Considerations for Sanction Assignment.” Accountability in Research 13 (2): 179–205. doi:https://doi.org/10.1080/08989620500440261.
- Li, D., and G. Cornelis. 2020. “Defining and Handling Research Misconduct: A Comparison between Chinese and European Institutional Policies.” Journal of Empirical Research on Human Research Ethics: JERHRE 15 (4): 302–319. doi:https://doi.org/10.1177/1556264620927628.
- Liao, Q. J., Y. Y. Zhang, Y. C. Fan, M. H. Zheng, Y. Bai, G. D. Eslick, -X.-X. He, S.-B. Zhang, H. H.-X. Xia, H. He, et al. 2018. “Perceptions of Chinese Biomedical Researchers Towards Academic Misconduct: A Comparison between 2015 and 2010.” Science and Engineering Ethics 24 (2): 629–645. doi:https://doi.org/10.1007/s11948-017-9913-3.
- Macchiarini, P. 2015. “Paolo Macchiarini Is Not Guilty of Scientific Misconduct.” Lancet (London, England) 386 (9997): 932. doi:https://doi.org/10.1016/S0140-6736(15)00118-X.
- Normile, D. 2021. “High-profile Chinese Scientist Cleared of Fraud and Plagiarism Charges Involving More than 60 Papers.” Science. doi:https://doi.org/10.1126/science.abg7078.
- Nouchi, R., H. Aihara, F. Arie, M. Asashima, H. Daida, J. Fudano, Y. Fujiwara, S. Fushiki, R. J. Geller, K. Hatano, et al. 2020. “Toward Global Standardization of Conducting Fair Investigations of Allegations of Research Misconduct.” Accountability in Research 27 (6): 327–346. doi:https://doi.org/10.1080/08989621.2020.1747019.
- OSTP. 2000. “Office of Science and Technology Policy.” Accessed 21 January 2021. https://ori.hhs.gov/content/chapter-2-research-misconduct-federal-policies
- Parrish, D. M. 2004. “Scientific Misconduct and Findings against Graduate and Medical Students.” Science and Engineering Ethics 10 (3): 483–491. doi:https://doi.org/10.1007/s11948-004-0006-8.
- Resnik, D. B., L. M. Rasmussen, and G. E. Kissling. 2015. “An International Study of Research Misconduct Policies.” Accountability in Research 22 (5): 249–266. doi:https://doi.org/10.1080/08989621.2014.958218.
- Resnik, D. B., and A. E. Shamoo. 2011. “The Singapore Statement on Research Integrity.” Accountability in Research 18 (2): 71–75. doi:https://doi.org/10.1080/08989621.2011.557296.
- Silver, A. 2019. “Chinese Ministry Investigates Duplications in Papers by University President.” Nature 576 (7785): 16–17. doi:https://doi.org/10.1038/d41586-019-03599-w.
- Teixeira da Silva, J. A. 2017. “Ethical Perspectives and Ramifications of the Paolo Macchiarini Case.” Indian journal of Medical Ethics 2 (4): 270–275. doi:https://doi.org/10.20529/IJME.2017.048.
- U.S. Food & Drug Administration. 2016. “What Is a Serious Adverse Event?” Accessed 12 February 2021. https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event
- Wilmshurst, P. 1997. “The Code of Silence.” Lancet (London, England) 349 (9051): 567–569. doi:https://doi.org/10.1016/S0140-6736(97)80121-3.